Imugene PRRS vaccine succeeds in pig trial
Preliminary results from Imugene’s recently completed pig trial in the US have been released. The results show that new modified PRRS vaccine Imugene’s [ASX:IMU] provides a very high degree of protection against the PRRS disease when two doses are administered either orally or by injection.
Porcine Reproductive and Respiratory Syndrome (PRRS) is caused by a viral infection. The major clinical signs are the result of areas of diseased lung (consolidation). To evaluate the severity of an infection, standardised lung lesion scores are generated by scoring the diseased areas in each of the 7 lung lobes from each pig and then generating an average.
Lesion score
Lesion score
The lower the average lung lesion score the better, as this indicates a lower level of disease. In addition, clinical illness slows weight gain during and after infection. An effective vaccine should result in less clinical illness and therefore better weight gains following infection.
Following challenge with the live PRRS virus, vaccinated pigs had much lower lung lesion scores and better weight gains over the 14 day post-challenge period compared to the unvaccinated control pigs.
Full report
Following challenge with the live PRRS virus, vaccinated pigs had much lower lung lesion scores and better weight gains over the 14 day post-challenge period compared to the unvaccinated control pigs.
Full report
The trials were undertaken at a specialist trial facility in the US. A full trial report including statistical analysis is being prepared and is expected in the next 4-6 weeks. Imugene will now use these results in discussions with major international animal health companies with a view to possible licensing agreements.
Related Website
• Imugene
Subscribe here to the Pig Progress newsletter
Related Website
• Imugene
Subscribe here to the Pig Progress newsletter
Join 18,000+ subscribers
Subscribe to our newsletter to stay updated about all the need-to-know content in the pigsector, three times a week.
